import{a,p as e,w as d}from"./chunk-4WY6JWTD-DiysjHVW.js";function o({children:s}){const t=a.useRef(null),[r,i]=a.useState(!1);return a.useEffect(()=>{const n=new IntersectionObserver(([c])=>{c.isIntersecting&&(i(!0),n.disconnect())},{threshold:.2});return t.current&&n.observe(t.current),()=>n.disconnect()},[]),e.jsx("div",{ref:t,className:`fade-in-section ${r?"visible":""}`,children:s})}function x(){return e.jsxs("section",{className:"relative h-[60vh] flex items-center justify-center bg-probentis-dark text-blue-500 overflow-hidden",children:[e.jsx("div",{className:"absolute inset-0 bg-linear-to-br from-blue-400 via-blue-200 to-blue-600"}),e.jsx(o,{children:e.jsxs("div",{className:"relative z-10 max-w-3xl mx-auto text-center px-4",children:[e.jsx("h1",{className:"text-4xl md:text-6xl font-bold drop-shadow-lg",children:"Transforming Prostate Cancer Detection"}),e.jsx("p",{className:"mt-6 text-lg md:text-xl text-blue-800 leading-relaxed drop-shadow-lg",children:"Probentis is developing a minimally invasive Raman spectroscopy device enabling real-time, in-vivo assessment to support better surgical outcomes."})]})})]})}function l({title:s,children:t,img:r,reverse:i}){return e.jsx(o,{children:e.jsx("section",{className:"py-20 bg-white",children:e.jsxs("div",{className:`container mx-auto px-6 flex flex-col md:flex-row items-center gap-12 ${i?"md:flex-row-reverse":""}`,children:[e.jsxs("div",{className:"flex-1",children:[e.jsx("h2",{className:"text-3xl font-bold text-probentis-dark mb-4",children:s}),e.jsx("div",{className:"text-gray-700 text-lg leading-relaxed",children:t})]}),r&&e.jsx("img",{src:r,alt:s,className:"flex-1 rounded-2xl shadow-xl w-full max-w-md"})]})})})}const u=d(function(){return e.jsxs(e.Fragment,{children:[e.jsx(x,{}),e.jsx(l,{title:"The Problem",img:"/images/focused-researcher.png",children:e.jsxs("ul",{className:"list-disc pl-6 space-y-2",children:[e.jsx("li",{children:"90,000 prostatectomies take place every year in the US."}),e.jsx("li",{children:"Surgeons currently rely on visual inspection to detect remaining cancer."}),e.jsx("li",{children:"Confirmation only happens after surgery via pathology."})]})}),e.jsx(l,{title:"Our Solution",img:"/images/glassware.png",reverse:!0,children:e.jsx("p",{children:"Probentis is developing a minimally invasive Raman spectroscopy device that performs real-time, in-vivo assessment of prostate tissue to detect the presence of cancer and grade its severity according to Gleason and ISUP systems."})}),e.jsx(l,{title:"State of Technology",img:"/images/lab-research.png",children:e.jsx("p",{children:"Our platform is backed by 7 years of scientific research, supported by MBIE Smart Ideas funding, and is advancing toward clinical translation."})})]})});export{u as default};
